David Emerson Jorden Net Worth

The estimated Net Worth of David Emerson Jorden is at least $6.08 Thousand dollars as of 14 June 2017. David Jorden owns over 32,727 units of PLx Pharma stock worth over $6,077 and over the last 8 years David sold PLXP stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

David Jorden PLXP stock SEC Form 4 insiders trading

David has made over 1 trades of the PLx Pharma stock since 2017, according to the Form 4 filled with the SEC. Most recently David bought 32,727 units of PLXP stock worth $225,162 on 14 June 2017.

The largest trade David's ever made was buying 32,727 units of PLx Pharma stock on 14 June 2017 worth over $225,162. On average, David trades about 16,364 units every 0 days since 2017. As of 14 June 2017 David still owns at least 151,913 units of PLx Pharma stock.

You can see the complete history of David Jorden stock trades at the bottom of the page.

What's David Jorden's mailing address?

David's mailing address filed with the SEC is 8285 El Rio St #130, Houston, TX 77054, USA.

Insiders trading at PLx Pharma

Over the last 8 years, insiders at PLx Pharma have traded over $0 worth of PLx Pharma stock and bought 841,160 units worth $2,548,334 . The most active insiders traders include West Asset Management Llc Park, Michael J Valentino, and David Emerson Jorden. On average, PLx Pharma executives and independent directors trade stock every 124 days with the average trade being worth of $2,403. The most recent stock trade was executed by Natasha Giordano on 15 March 2022, trading 4,100 units of PLXP stock currently worth $14,965.

What does PLx Pharma do?

PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.

Complete history of David Jorden stock trades at PLx Pharma

PLx Pharma executives and stock owners

PLx Pharma executives and other stock owners filed with the SEC include:

• Natasha Giordano,
  CEO, Pres & Director
• Robert Shawah,
  Chief Accounting Officer, Treasurer
• Rita M. O'Connor CPA, CPA,
  CFO and Head of Manufacturing & Supply Chain
• Michael J. Valentino,
  Exec. Chairman
• Michael Valentino,
  Director
• John Hadden,
  Director
• Natasha Giordano,
  Director
• Robert Casale,
  Director
• Kirk Calhoun,
  Director
• Anthony Bartsh,
  Director
• Gary Balkema,
  Director
• Tom Long,
  Vice President - Manufacturing & Technical Operations
• Steven Valentino,
  Vice President - Trade Sales
• Rita O Connor,
  Chief Financial Officer
• Harris Kaplan M.B.A., MBA,
  Member of Chief Exec. Officer Advisory Group
• Janet M. Barth,
  VP of Investor Relations & Corp. Communications
• Harris Kaplan MBA,
  Member of Chief Exec. Officer Advisory Group
• Charles Edmund Sheedy C.F.A., CFA,
  Member of Chief Exec. Officer Advisory Group
• Patrick M. Lonergan,
  Member of Chief Exec. Officer Advisory Group
• Nicole Godino,
  National Sales Director
• Joanne Cotignola,
  VP of Marketing
• Ronald R. Zimmerman,
  Founder & Sr. Advisor
• Efthymios Deliargyris,
  Chief Medical Officer
• West Asset Management Llc Park,
  10% owner
• David Emerson Jorden,
  Acting Chief Financial Officer
• Gary L Mossman,
  Chief Operating Officer
• David P Luci,
  Director